Showing 4571-4580 of 5957 results for "".
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Productshttps://modernod.com/news/thea-completes-its-acquisition-of-akorns-branded-ophthalmic-products/2480688/Théa Pharma announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn. The transaction expands Théa’s eye care portfolio in the United States. Financial terms of the deal were not disclosed. &
- DORC Launches Eva Nexushttps://modernod.com/news/dorc-launches-eva-nexus/2480687/DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in retina, cataract and combined surgery. Eva Nexus introduces multiple innovations in surgical performance and efficiency, including SmartIOP that combines with the existing E
- Lighthouse Guild Opens Technology Center for People Who are Blind or Visually Impairedhttps://modernod.com/news/lighthouse-guild-opens-technology-center-for-people-who-are-blind-or-visually-impaired/2480685/Lighthouse Guild Technology Center, which offers people who are blind or visually impaired access to the latest assistive devices and state-of-the-art technology, celebrated its official opening. The Center occupies 11,000 square feet at Lighthouse Guild’s New York City headquarters and is
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure
- Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/Ocuphire Pharma announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM) in 23 pediatric subjects. Ocuphire worked closely with Oculos Develop
- Alcon Launches Clareon IOL Portfolio in the UShttps://modernod.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/Alcon announced the launch of the Clareon family of IOLs in the United States. Utilizing an advanced IOL material, Clareon is designed to deliver consistent visual outcomes and clarity that lasts.[1-7] The Clareon clarity is born out of a glistening-free IOL material that has among
- LumiThera Completes Acquisition of Diopsyshttps://modernod.com/news/lumithera-completes-acquisition-of-diopsys/2480675/LumiThera announced the completion of its acquisition of Diopsys, a provider of modern visual electrophysiology medical devices. Diopsys is now a wholly owned subsidiary of LumiThera. Financial terms the transaction were not disclosed. EyewireTV's covereage of the acq
- Santen Establishes its First External Research Laboratory in Europe at the UCL Institute of Ophthalmology in Londonhttps://modernod.com/news/santen-establishes-its-first-external-research-laboratory-in-europe-at-the-ucl-institute-of-ophthalmology-in-london/2480674/Santen, in partnership with UCL Institute of Ophthalmology (IoO), has announced the company’s first external research laboratory in Europe. This development comes following ongoing and committed investment from Santen
- Accure Therapeutics Licenses Neuroprotective Drug Candidate to Oculishttps://modernod.com/news/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus/2480672/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic